Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Feasibility and utility of synthetic control arms derived from real-world data to support clinical development.
Authors
Jaclyn Paige Lyman
Parker Institute for Cancer Immunotherapy, San Francisco, CA
Jaclyn Paige Lyman , Abigail Doucette , Binbin Zheng-Lin , Christopher R. Cabanski , Molly A. Maloy , Nicholas L. Bayless , Jingying Xu , William Smith , Joyson Joseph Karakunnel , Justin P. Fairchild , Ramy Ibrahim , Eileen Mary O'Reilly , Robert H. Vonderheide , Peter Edward Gabriel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
DOI
10.1200/JCO.2022.40.4_suppl.528
Abstract #
528
Poster Bd #
E10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Jaclyn P. Lyman
Poster
2021 ASCO Annual Meeting
Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (Sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results.
First Author: Mark H. O'Hara
Poster
2023 ASCO Annual Meeting
Overall survival of patients with BRAF-mutant metastatic colorectal cancer treated with encorafenib-cetuximab in a real-world nationwide study in the Netherlands.
First Author: Sietske C.M.W. van Nassau
Poster
2023 ASCO Annual Meeting
Outcomes of patients with advanced EGFR mutant lung cancer treated with first line (1L) osimertinib (osi) who would not have met eligibility criteria for the FLAURA trial.
First Author: Connor Wells